Immunoblastic sarcoma of the B-cell type in the CSF light- and electronmicroscopic study of the malignant cells and unusual macrophages

S, Pelc; Fondu, Pierre; Otten, Jacques; Gompel, C

doi:10.1007/bf00690992

Cited by 7 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to our own patients we reviewed the literature of the last 10 years for well-documented patients with primary CNS-NHL (2,10,11,12,16,18,25,27,28,32,39,43,46,47,55,56,57,58,65,66,68,69,70,73). Histologic diagnoses of cases from the literature were translated to the equivalent histologic subtypes of the Kiel-classification according to recommendations by Lennert (33) and the working formulation (44).…”

Section: Review Of the Literaturementioning

confidence: 99%

Primary non-Hodgkin's lymphomas of the CNS

Bogdahn

Mertens

et al. 1986

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

This paper reports on 10 patients (4 male, 6 female) with primary non-Hodgkin's lymphomas of the brain (CNS-NHL--mean age 46.8 years, mean postdiagnostic survival 10 months). Pathological CSF (cerebrospinal fluid) was found in all 8 patients examined (positive cytology in 7/8 cases). Solitary tumors, diffuse periventricular infiltration or diffuse cerebral infiltration were demonstrated in cerebral computer-assisted tomography (CAT). Angiographical findings were unspecific. The histologic subtypes were lymphoplasmacytoid immunocytoma (4), unclassified low grade (1), centroblastic (1), B-immunoblastic (1), T-immunoblastic (1), lymphoblastic convoluted T-cell type (1), unclassified high grade (1) NHL. Patients who had received radiotherapy (+/- surgery) in this group had a mean survival of 15.66 months (sigma = 7.63). In addition, an overview of 83 well-documented, cases of the literature tries to characterize main histological and topographical distributions, histology-, patient's age-, and therapy-related survival. Patients with primary CNS-NHL have a 5-year survival expectancy of 30% compared with 2.3% in secondary CNS-manifestations of systemic non-Hodgkin's lymphomas. In this report, the beneficial effect of radiotherapy (mean survival 30.3 months) compared to surgery or symptomatic treatment (3.6 or 3.3 months) could be confirmed. It is concluded that primary CNS-NHL frequently present with atypical neuropsychiatric syndromes; diagnosis should be established preferentially with CAT and CSF-examinations or stereotactic biopsies, whereas open surgery should be avoided. An approach to exact classification should be attempted, as survival is clearly related to histological subtypes.

show abstract

Section: Review Of the Literaturementioning

confidence: 99%

Primary non-Hodgkin's lymphomas of the CNS

Bogdahn

Mertens

et al. 1986

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

Developments in the diagnosis and treatment of primary CNS lymphoma: A prospective series

Neuwelt

Frenkel

Gumerlock

et al. 1986

Cancer

116

View full text Add to dashboard Cite

Current experience with 12 patients studied prospectively suggests a new approach in the diagnosis and treatment of primary central nervous system (CNS) lymphoma, integrating the techniques of needle brain biopsy, immunohistochemical staining for monoclonal antibody and chemotherapeutic drug delivery in association with blood-brain barrier modification. Computed tomography (CT)-guided needle biopsy of deep parenchymal lesions contributed to the diagnosis in six patients. Immunohistochemical staining methods detected monoclonal immunoglobulins in those patients so tested. Following diagnosis, the patients have been treated with multi-agent chemotherapy in conjunction with osmotic blood-brain barrier modification (five without antecedent cranial irradiation) with an initial complete response rate by CT scan in nine patients, a median follow-up of 19 months from diagnosis, and a 1-year survival of 75%. This experience emphasizes the value of CT-guided stereotaxic or CT-guided needle biopsy, which limits the need for therapy without a diagnosis or the need for a major craniotomy in what are commonly deep, paraventricular lesions. Immunoperoxidase cytochemical stains can detect monoclonal immunoglobulin characteristic of CNS B-cell malignant lymphomas and provide an important diagnostic aid when only modest quantities of tissue or cells are obtained. Finally, chemotherapy administered in conjunction with osmotic blood-brain barrier modification results in a clinical response rate and survival that are at least as effective as radiotherapy as a primary therapeutic modality.

show abstract

Primäre und sekundäre Lymphome des Zentralnervensystems

Jellinger¹

1983

Hämoblastosen Zentrale Motorik Iatrogene Schäden Myositiden

View full text Add to dashboard Cite

Immunoblastic sarcoma of the B-cell type in the CSF light- and electronmicroscopic study of the malignant cells and unusual macrophages

Cited by 7 publications

References 13 publications

Primary non-Hodgkin's lymphomas of the CNS

Primary non-Hodgkin's lymphomas of the CNS

Developments in the diagnosis and treatment of primary CNS lymphoma: A prospective series

Primäre und sekundäre Lymphome des Zentralnervensystems

Contact Info

Product

Resources

About